GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Clinical Oncology (ASCO)  (3)
  • 2010-2014  (3)
Material
Publisher
  • American Society of Clinical Oncology (ASCO)  (3)
Person/Organisation
Language
Years
  • 2010-2014  (3)
Year
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    Correlation between anthropometric, pathologic data, and 21-gene recurrence score assay in early-stage breast cancer.
    American Society of Clinical Oncology (ASCO) ; 2013
    In:  Journal of Clinical Oncology Vol. 31, No. 15_suppl ( 2013-05-20), p. 1591-1591
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 15_suppl ( 2013-05-20), p. 1591-1591
    Abstract: 1591 Background: Obesity or body mass index (BMI) 〉 30kg/m 2 is a grave public health concern. Poorer outcome has been documented in obese breast cancer patients. We report the use of the Oncotype Dx Recurrence Score (RS) assay and its correlation with BMI and pathologic data. Methods: Study period: 01/09/08 – 31/05/12. Data was derived from: MWCC database; pathology reports; patient files; RS reports. Statistical analysis was carried out using R. Results: 89 patients were found. Median follow-up: 21.4 months. See Table for data. Conclusions: For this cohort: A skewed pattern in RS assay scores was observed in obese patients, where there were more intermediate and high scores, although this was not significant in multivariate model; tumour size and grade were shown to correlate with the RS assay results; these findings are thought-provoking and certainly can augment to the accruing energy balance data that has been increasingly of interest in oncological research. [Table: see text]
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2013.31.15_suppl.1591
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2013
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Pre-morbid anthropometric measurement and its impact on outcome in early-stage breast cancer in midwestern Ireland.
    American Society of Clinical Oncology (ASCO) ; 2013
    In:  Journal of Clinical Oncology Vol. 31, No. 26_suppl ( 2013-09-10), p. 45-45
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 31, No. 26_suppl ( 2013-09-10), p. 45-45
    Abstract: 45 Background: Obesity has become a grave public health concern of global proportions, especially in many developed counties. Clinical obesity may be defined as a body mass indeed (BMI) of greater than or equal to 30kg/m 2 . Within recent times, growing interest has been seen for the relationship between obesity and cancer; with it being identified as a significant risk factor. It has also been appreciated that it is one of the greatest modifiable risk factors for malignancy. Obesity at the time of diagnosis of early-stage breast cancer (EBC) has been associated with poor outcome, especially breast-cancer specific survival. The potential mechanism for this has been linked to several factors including: associated adverse disease features; hormonal influences; co-morbidities that can interfere with therapy; and other yet unknown pathways. We herein report our experience on patients with newly diagnosed EBC and related pre-morbid anthropometric data and its impact on their outcome in an ambulatory Medical Oncology practice in Mid-Western Ireland. Methods: Study period: 01/01/2001 – 31/12/2010. Retrospective data was derived from (1) MWCC Oncology database, (2) pathology reports, and (3) patient files. Data was collated and entered into an Access database and exported into IBM SPSS Statistics 20 version for statistical analysis. Results: One thousand and forty-one (1,041) patients with EBC were identified and analysed. Median age: 55 years (23 – 87 years). Median follow-up: 5.04 years. BMI distribution revealed: Underweight ( 〈 18.5kg/m 2 ): 1%; Normal (18.5 – 25kg/m 2 ): 33%; Overweight (25.1 – 30kg/m 2 ): 39%; and Obese ( 〉 30kg/m 2 ): 27%. It was noted that obese patients had disproportionately later age of presentation, larger tumours, ductal carcinoma on histology and a smoking history (including current and former smokers). Obese patients accounted for 50% of the non-cancer related deaths observed. Obese patients showed poorer survival in all categories, but it was only statistically significant for non-cancer related deaths. Conclusions: Pre-morbid anthropometric data has shown that obese patients had poorer outcome, and highlights that potential intervention can have impact on improving outcome in EBC.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2013.31.26_suppl.45
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2013
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Correlation between 21-gene recurrence score assay with Nottingham prognostic index (NPI) and Adjuvant! Online (AO) prognostic tools in newly diagnosed patients with early-stage breast cancer in midwestern Ireland.
    American Society of Clinical Oncology (ASCO) ; 2012
    In:  Journal of Clinical Oncology Vol. 30, No. 15_suppl ( 2012-05-20), p. e16551-e16551
    Details
    In: Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. e16551-e16551
    Abstract: e16551 Background: Prognostic tools such as NPI and AO have been used to help stratify early stage breast cancer patients into specific risk-related groupings. With the development of molecular biological gene expression assays, both predictive and prognostic information for patients with early stage endocrine positive breast cancer can be determined. We herein report our experience with the use of a 21-gene recurrence score (RS) assay, it’s correlation with NPI and AO, and explore the comparative outcome for patients in MWCC, Limerick, Ireland. Methods: Study period: 01/09/2008 – 31/12/2012. Data was derived from (1) MWCC Oncology database (2) MWRH pathology reports (3) MWRH patient files (4) RS assay reports. Data was collated and entered into an Access database and exported into Predictive Analytics Software for analysis. Results: Seventy-seven (77) patients with early stage endocrine positive breast cancer were analysed. Median age: 55.9 years (range: 30.6 – 72.3 years). Median follow-up: 15.4 months. NPI distribution was: excellent – 9%, good – 53%, moderate – 38% and poor – 0%, with median NPI score – 3.36. RS distribution was: low – 49%, intermediate – 43% and high – 8%, with median RS – 18. The RS correlated poorly with NPI predictions. The median AO benefit 10-year survival with no additional therapy – 81.4%, the median AO additional benefit 10-year survival of chemotherapy (CT) – 1.2% and median AO additional benefit 10-year survival of CT and hormonal therapy (HT) – 3.9%. The RS also correlated poorly with AO predictions. Conclusions: Prognostic tools are useful in evaluating and predicting the possible outcome, but they do not correlate well with this 21-gene RS molecular assay, as seen with our cohort. These tools should therefore be used in tandem, together with good clinical judgement on an individual basis when advising patients on potential treatment pathways. Further long term evaluation is required.
    Type of Medium: Online Resource
    ISSN: 0732-183X , 1527-7755
    URL: Article
    DOI: 10.1200/jco.2012.30.15_suppl.e16551
    RVK:
    XA 52760
    RVK:
    XA 10000
    Language: English
    Publisher: American Society of Clinical Oncology (ASCO)
    Publication Date: 2012
    detail.hit.zdb_id: 2005181-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...